Carondelet Health Network, Tucson, AZ

Carondelet Health Network

www.carondelet.org

Headquartered in Tucson, Ariz., Carondelet Health Network is committed to providing Southern Arizonans with a full spectrum of high-quality, cost-efficient care and improving the quality of life for all those who enter its doors. As the region’s only Catholic hospital system, Carondelet is jointly owned by Tenet Healthcare Corporation, Dignity Health and Ascension, Carondelet is operated by majority partner Tenet, a leading diversified healthcare services company.

Number of Employees: 0-25
Annual Revenue: $500M-1 Billion

www.carondelet.org
1601 W Saint Marys Rd
Tucson, AZ USA 85745-2623
Phone: 520.873.3000

Similar Companies

MedSynergies

MedSynergies partners with health care organizations and physicians to align their operations by providing revenue cycle management, practice management, consulting services, business process analysis and software integration solutions.

Discovery Laboratories Inc

Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.

CTOs on the Move